

REMARKS/ARGUMENTS

Applicants thank the Examiner for the interview on April 21, 2008, with regard to the discrepancy discovered between the latest Sequence Listing and the first Sequence Listing filed in the captioned application. Specifically, sequence number three is in question.

The Sequence Listing filed on May 17, 2002 was in response to a missing parts notice and contained sequence numbers one through three. It was identical to the one filed on February 8, 2002 with the initial application filing papers. Sequence number three contained 830 amino acids, and this was an overlooked error, as it actually contains 832. With regard to the Sequence Listing the Examiner points out as being filed on June 12, 2002, Applicants have no record.

The Sequence Listing filed on October 10, 2006 was in response to an Office Communication indicating that there were more than three sequences in the application. Applicants filed a revised Sequence Listing adding sequences four and five as found in the specification. The Sequence Listing filed on August 27, 2007 added sequences six through sixteen as found in Figures six through thirteen, per the Examiner's instructions. The Sequence Listing filed on January 7, 2008 was in response to an error report generated on the Sequence Listing filed August 27, 2007. Applicants corrected the errors.

Applicants wish to point out that the Sequence Listing filed on May 17, 2002 was produced by transcription from paper to PatentIn. Sequence number three was

copied from Figure 3. Typographical errors were introduced during the generation of the Sequence Listing, such that two amino acid sequences from Figure 3 were left out in sequence number three of the Sequence Listing. Applicants submit that this was merely a typographical error and in no way meant any deception. The later sequences filed using the later versions of PatentIn allowed for a copy and paste of the sequence from Figure 3 as originally filed, and this accounts for the correct number of amino acids in sequence number three appearing in the later filed Sequence Listings.

Applicants respectfully submit that no new matter is introduced. A notice of allowance for pending claims 15 and 23-28 is earnestly requested.

Early and favorable consideration is respectfully requested.

Respectfully submitted,

GE Healthcare Bio-Sciences Corp.

By:



Yonggang Ji

Reg. No.: 53,073

Agent for Applicants

GE Healthcare Bio-Sciences Corp.
800 Centennial Avenue
P. O. Box 1327
Piscataway, New Jersey 08855-1327

Tel: (732) 980-2875
Fax: (732) 457-8463

I hereby certify that this correspondence is being uploaded to the United States Patent and Trademark Office using the Electronic Filing System on June 6, 2008.

Signature: 

Name: Melissa Leck